The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.
June 6th 2025
Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.
Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.